DOCSLIB.ORG

The Invention and Development of Enflurane, Isoflurane, Sevoflurane

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Invention and Development of Enflurane, Isoflurane, Sevoflurane Ⅵ CLASSIC PAPERS REVISITED David S. Warner, M.D., Editor Anesthesiology 2008; 108:531–3 Copyright © 2008, the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. The Invention and Development of Enflurane, Isoflurane, Sevoflurane, and Desflurane Ross C. Terrell, Ph.D.* Reprinted with permission from: Terrell RC, Speers L, Szur AJ, Eleven of the ethers were too unstable to test, Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/108/3/531/366681/0000542-200803000-00025.pdf by guest on 25 September 2021 Treadwell J, Ucciardi TR: General anesthetics: 1. Halogenated and, of the remaining 25, 13 had promising an- methyl ethyl ethers as anesthetic agents. J Med Chem 1971; esthetic properties in mice and are suitable for 14:517–9. Copyright 1971 American Chemical Society. study in larger animals. Those ethers having one H with at least 2 halogens other than F or 2 or Thirty-six halogenated Me Et ethers have been more H with at least one Br or Cl were the best synthesized for evaluation as volatile anesthetics. anesthetics. THE anesthetic properties of several fluorinated hydro- came the market leader. Fluoroxene and methoxyflurane carbons were reported by Robbins1 in 1946. In the were less successful because fluoroxene was borderline period 1946–1959, three fluorinated compounds, two flammable and caused serious postoperative nausea and ethers, and one hydrocarbon were introduced into clin- vomiting. The high boiling point (102°C) and high lipid ϭ ical practice: fluoroxene (CF3CH2OCH CH2) by Ohio solubility of methoxyflurane resulted in long recovery Medical Products (Cleveland, OH) in 1951, halothane times, and some renal toxicity probably due to a high (CF3CHClBr) by Ayerst Laboratories (New York, NY) and degree of metabolism. Imperial Chemical Industries, PLC (London, England) in This was the “state of the art” around 1960 when Ohio 1955, and methoxyflurane (CH3OCF2CHCl2) by Abbott Medical Products (a small division of Airco, Inc.) initi- Laboratories (Abbott Park, IL) in 1959. Although several ated a research project, the goal of which was to syn- other fluorinated ethers and hydrocarbons were re- thesize a new volatile anesthetic at least equal to, but ported to have anesthetic properties, none were success- hopefully better than, halothane, the market leader at fully marketed.2 Halothane was an immediate success the time. This was a logical project for Ohio Medical because it was potent and nonflammable with a very Products because they were already in the anesthetic acceptable anesthetic syndrome. It was especially useful market with nitrous oxide, cyclopropane, medical oxy- for mask inductions in children. There were, however, gen, the somewhat unsuccessful fluoroxene, and some three problems associated with halothane, less than ideal other anesthesia-related hardware. A new improved in- cardiovascular properties, the occurrence of rare but halation anesthetic would have been a valuable addition serious hepatic toxicity, and a substantial degree of me- to the product line. Ohio Medical Products assigned two tabolism. Despite these problems, halothane rapidly be- senior chemists, Louise Speers Croix, Ph.D. (1920–1992), and me to the project. I remember that at the time, several of our colleagues told us that we didn’t have a chance to Additional material related to this article can be found on the compete with the large companies, Abbott Laboratories, ANESTHESIOLOGY Web site. Go to http://www.anesthesiology .org, click on Enhancements Index, and then scroll down to find Imperial Chemical Industries, or Ayerst, who probably had the appropriate article and link. Supplementary material can also done or were doing considerable research on new anes- be accessed on the Web by clicking on the “ArticlePlus” link thetics. History shows that they had not and were not. either in the Table of Contents or at the top of the Abstract or We were not discouraged, and over the next 10 or 15 yr, HTML version of the article. we synthesized several hundred new fluorinated com- pounds, four of which—enflurane (CHF2OCF2CHFCl), * Vice President (Retired). Current position: Research Associate. isoflurane (CF3CHClOCHF2), sevoflurane (CF3)2CHOCH2F, Received from Minrad, Inc., Orchard Park, New York. Submitted for publica- and desflurane (CF3CHFOCHF2)—are currently used in tion July 20, 2007. Accepted for publication November 20, 2007. The research clinical practice. Some of the most important work on the for and preparation of this revisited article were supported solely by the author’s personal funds. synthesis of fluorinated methyl ethyl ethers and fluorinated Address correspondence to Dr. Terrell: Minrad, Inc., 50 Cobham Drive, Or- methyl isopropyl ethers, which resulted in the discovery of chard Park, New York 14127-1421. [email protected]. This article may be enflurane, isoflurane, sevoflurane, and desflurane, has been accessed for personal use at no charge through the Journal Web site, www 3–6 .anesthesiology.org. published. Most of the other work on fluorinated hydro- Anesthesiology, V 108, No 3, Mar 2008 531 532 ROSS C. TERRELL carbons, fluorinated diethyl ethers, and methyl-n-propyl well be as good an anesthetic as sevoflurane. Stability to ethers has not been published except in the patent litera- soda lime should be similar and possibly better because ture, although many compounds were synthesized in these the –OCHF2 group should be more stable than the areas. –OCH2F group in sevoflurane. This structure may be The research project was unique in several ways. There related to the decomposition of sevoflurane caused by were four general requirements. First, volatility was neces- iron oxide and aluminum oxide.12 There has been one sary. This limited syntheses, with few exceptions, to com- product recall of sevoflurane because of decomposition pounds having no more that four carbon atoms. Second, caused by iron oxide. nonflammability. This limited the number of hydrogen at- There are several other compounds that were not devel- oms. Fortunately, hydrogen could be substituted with chlo- oped by Ohio Medical Products, not because of instability to rine or fluorine and still retain some anesthetic properties. soda lime but rather because of low potency resulting from Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/108/3/531/366681/0000542-200803000-00025.pdf by guest on 25 September 2021 Third, stability, especially to soda lime. This requirement low solubility. There are four compounds of possible interest, 2 3 2 3 effectively excluded groups such as CH2ClO–, generally CHF2OCF2CF2Cl, CHF2OCF2CF2H, CF2ClOCF CHF2, and 3 known to be unstable to base, as well as some other CH2FOCF2CHF2, which is claimed to have good analgesia at groups. Fourth, a synthesis that could be used to manufac- subanesthetic concentrations.13 ture relatively large quantities at a reasonable price. This is There were also many other compounds, diethyl ethers, in contrast to the usual pharmaceutical product where the methyl propyl ethers, and assorted hydrocarbons, which active ingredient is usually measured in pounds. For anes- were volatile and stable to soda lime. None had acceptable thetics, the quantity is measured in tons. Current annual anesthetic properties. The data on most of these have not production of volatile anesthetics is estimated to be well been published. over 2,000 tons. Following this fourth guideline, much of Data on the large number of fluorinated compounds the work was done using readily available starting materi- synthesized allow some general structure–activity rela- ϭ als, such as CF2 CFCl, the starting material for enflurane; tions to be deduced. For example, fully halogenated CF3CH2OH and CF2HCl (freon 22), the starting materials compounds are usually poor anesthetics or are convul- for isoflurane and desflurane; and (CF3)2CH–OH, the start- sants. Other correlations can be made, but there are no ing material for sevoflurane. The most valuable synthetic really definite structure–activity relations that can be route used was photochemical chlorination, followed by used to accurately predict whether a compound will be replacement of the chlorine by fluorine. The Swarts reac- a good anesthetic. It is fortunate and somewhat amazing, tion, discovered around 1895, which used SbF3 or HF at least to me, that there is any correlation at all between 7 catalyzed by SbCl5, was the most useful. Chorine could pharmacologic activity and a structural formula as writ- also be substituted using potassium fluoride or other fluo- ten on paper. ride salts, also a well-known reaction.7 Predictions of activity based on structural formulae It would have been simpler to replace hydrogen di- often fail. A striking example of this is hexafluorodiethyl rectly using elemental fluorine rather than first chlorinat- ether, CF3CH2OCH2CF3, which might be predicted to be ing and then replacing the chlorine with fluorine. How- anesthetic because the structure is similar to that of ever, elemental fluorine is so reactive that the reaction is diethyl ether. It is not and is, in fact, a potent convulsant exceedingly difficult to control. Some research was done marketed by Ohio Medical Products as an alternative to on this method, and the first sample of desflurane was electroshock therapy. synthesized by this method.8 We also produced several Are there other compounds possible that have not yet fires, and this synthetic route was soon abandoned. been synthesized and tested? To possibly answer this Even with the somewhat strict guidelines and the lim- question, I did the following study, which I believe is ited synthetic methods available, it was possible to syn- unique to the anesthetic project because one can calcu- thesize several hundred fluorinated compounds for test- late the total number of compounds possible, both ing as anesthetic agents. Most of the compounds failed ethers and hydrocarbons having four carbon atoms or when tested in mice, but three did not—enflurane, less and any combination of hydrogen, fluorine, chlo- isoflurane, and desflurane.9,10 These three were all pat- rine, and bromine. This could never be done for any ented as anesthetics and are currently approved and other group of pharmaceutical products.
Load more

Recommended publications
  • Management of Chronic Problems
    MANAGEMENT OF CHRONIC PROBLEMS INTERACTIONS BETWEEN ALCOHOL AND DRUGS A. Leary,* T. MacDonald† SUMMARY concerned. Alcohol may alter the effects of the drug; drug In western society alcohol consumption is common as is may change the effects of alcohol; or both may occur. the use of therapeutic drugs. It is not surprising therefore The interaction between alcohol and drug may be that concomitant use of these should occur frequently. The pharmacokinetic, with altered absorption, metabolism or consequences of this combination vary with the dose of elimination of the drug, alcohol or both.2 Alcohol may drug, the amount of alcohol taken, the mode of affect drug pharmacokinetics by altering gastric emptying administration and the pharmacological effects of the drug or liver metabolism. Drugs may affect alcohol kinetics by concerned. Interactions may be pharmacokinetic or altering gastric emptying or inhibiting gastric alcohol pharmacodynamic, and while coincidental use of alcohol dehydrogenase (ADH).3 This may lead to altered tissue may affect the metabolism or action of a drug, a drug may concentrations of one or both agents, with resultant toxicity. equally affect the metabolism or action of alcohol. Alcohol- The results of concomitant use may also be principally drug interactions may differ with acute and chronic alcohol pharmacodynamic, with combined alcohol and drug effects ingestion, particularly where toxicity is due to a metabolite occurring at the receptor level without important changes rather than the parent drug. There is both inter- and intra- in plasma concentration of either. Some interactions have individual variation in the response to concomitant drug both kinetic and dynamic components and, where this is and alcohol use.
    [Show full text]
  • Euthanasia of Experimental Animals
    EUTHANASIA OF EXPERIMENTAL ANIMALS • *• • • • • • • *•* EUROPEAN 1COMMISSIO N This document has been prepared for use within the Commission. It does not necessarily represent the Commission's official position. A great deal of additional information on the European Union is available on the Internet. It can be accessed through the Europa server (http://europa.eu.int) Cataloguing data can be found at the end of this publication Luxembourg: Office for Official Publications of the European Communities, 1997 ISBN 92-827-9694-9 © European Communities, 1997 Reproduction is authorized, except for commercial purposes, provided the source is acknowledged Printed in Belgium European Commission EUTHANASIA OF EXPERIMENTAL ANIMALS Document EUTHANASIA OF EXPERIMENTAL ANIMALS Report prepared for the European Commission by Mrs Bryony Close Dr Keith Banister Dr Vera Baumans Dr Eva-Maria Bernoth Dr Niall Bromage Dr John Bunyan Professor Dr Wolff Erhardt Professor Paul Flecknell Dr Neville Gregory Professor Dr Hansjoachim Hackbarth Professor David Morton Mr Clifford Warwick EUTHANASIA OF EXPERIMENTAL ANIMALS CONTENTS Page Preface 1 Acknowledgements 2 1. Introduction 3 1.1 Objectives of euthanasia 3 1.2 Definition of terms 3 1.3 Signs of pain and distress 4 1.4 Recognition and confirmation of death 5 1.5 Personnel and training 5 1.6 Handling and restraint 6 1.7 Equipment 6 1.8 Carcass and waste disposal 6 2. General comments on methods of euthanasia 7 2.1 Acceptable methods of euthanasia 7 2.2 Methods acceptable for unconscious animals 15 2.3 Methods that are not acceptable for euthanasia 16 3. Methods of euthanasia for each species group 21 3.1 Fish 21 3.2 Amphibians 27 3.3 Reptiles 31 3.4 Birds 35 3.5 Rodents 41 3.6 Rabbits 47 3.7 Carnivores - dogs, cats, ferrets 53 3.8 Large mammals - pigs, sheep, goats, cattle, horses 57 3.9 Non-human primates 61 3.10 Other animals not commonly used for experiments 62 4.
    [Show full text]
  • Pharmacology – Inhalant Anesthetics
    Pharmacology- Inhalant Anesthetics Lyon Lee DVM PhD DACVA Introduction • Maintenance of general anesthesia is primarily carried out using inhalation anesthetics, although intravenous anesthetics may be used for short procedures. • Inhalation anesthetics provide quicker changes of anesthetic depth than injectable anesthetics, and reversal of central nervous depression is more readily achieved, explaining for its popularity in prolonged anesthesia (less risk of overdosing, less accumulation and quicker recovery) (see table 1) Table 1. Comparison of inhalant and injectable anesthetics Inhalant Technique Injectable Technique Expensive Equipment Cheap (needles, syringes) Patent Airway and high O2 Not necessarily Better control of anesthetic depth Once given, suffer the consequences Ease of elimination (ventilation) Only through metabolism & Excretion Pollution No • Commonly administered inhalant anesthetics include volatile liquids such as isoflurane, halothane, sevoflurane and desflurane, and inorganic gas, nitrous oxide (N2O). Except N2O, these volatile anesthetics are chemically ‘halogenated hydrocarbons’ and all are closely related. • Physical characteristics of volatile anesthetics govern their clinical effects and practicality associated with their use. Table 2. Physical characteristics of some volatile anesthetic agents. (MAC is for man) Name partition coefficient. boiling point MAC % blood /gas oil/gas (deg=C) Nitrous oxide 0.47 1.4 -89 105 Cyclopropane 0.55 11.5 -34 9.2 Halothane 2.4 220 50.2 0.75 Methoxyflurane 11.0 950 104.7 0.2 Enflurane 1.9 98 56.5 1.68 Isoflurane 1.4 97 48.5 1.15 Sevoflurane 0.6 53 58.5 2.5 Desflurane 0.42 18.7 25 5.72 Diethyl ether 12 65 34.6 1.92 Chloroform 8 400 61.2 0.77 Trichloroethylene 9 714 86.7 0.23 • The volatile anesthetics are administered as vapors after their evaporization in devices known as vaporizers.
    [Show full text]
  • Objective Salicylate Propionic Acid Derivatives Acetic Acid
    Semester-IV Sub Name-medicinal chemistry-I (sub code-BP-402T) Objective Sodium salicylate, Aspirin, Mefenamic acid*, Meclofenamate, Indomethacin, Sulindac, Tolmetin, Zomepriac, Diclofenac, Ketorolac, Ibuprofen*, Naproxen, Piroxicam, Phenacetin, Acetaminophen, Antipyrine, Phenylbutazone. 1. INTRODUCTION A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti- inflammatory agents block certain substances in the body that cause inflammation. They are used to treat many different conditions. Some anti-inflammatory agents are being studied in the prevention and treatment of cancer. 1.1 CLASSIFICATION NSAIDs can be classified based on their chemical structure or mechanism of action. Older NSAIDs were known long before their mechanism of action was elucidated and were for this reason classified by chemical structure or origin. Newer substances are more often classified by mechanism of action. Salicylate • Aspirin (acetylsalicylic acid) • Diflunisal (Dolobid) • Salicylic acid and its salts Propionic acid derivatives • Ibuprofen • Dexibuprofen • Naproxen • Fenoprofen • Ketoprofen • Dexketoprofen Acetic acid derivatives • Indomethacin • Tolmetin • Sulindac • Ketorolac • Diclofenac • Aceclofenac • Nabumetone (drug itself is non-acidic but the active, principal metabolite has a carboxylic acid group) Enolic acid (oxicam) derivatives • Piroxicam • Meloxicam • Tenoxicam • Droxicam • Lornoxicam • Isoxicam (withdrawn from market 1985) • Phenylbutazone Anthranilic acid derivatives (fenamates) The following NSAIDs are
    [Show full text]
  • Introduction and Definition Criteria for Evaluating Methods of Euthanasia Indications for Euthanasia Methods of Euthanasia
    EUTHANASIA Lyon Lee DVM PhD DACVA Introduction and definition • Many of the contents presented here are excerpts from 2000 Report of the AVMA Panel on Euthanasia (JAVMA 218 (5), 2001) • Euthanasia is a word of Greek origin, a rough translation being Good death o Webster English Dictionary The act or practice of painlessly putting to death o Oxford English Dictionary The action of inducing a gentle and easy death o Good death is one that occurs with minimal pain and distress o Euthanasia is, therefore, an act of inducing death in hopelessly unwell or injured animals in a pain free manner on the grounds of humanity Criteria for evaluating methods of euthanasia • It must be painless and not induce fear or apprehension in the animal • It must be reliable • It must be rapid • It must be safe and simple to operate • It must be nonreversible • It should be inexpensive • It should as far as possible be aesthetic • It should be possible to observe the animals at all times • It should be safe for predators/consumers should the carcass be consumed Indications for euthanasia • Required as an experimental procedure • Sustained a severe injury that is difficult to manage • The animal is in excruciating pain refractory to the treatment • On demand by the authority (State or Federal inspectors, IACUC etc.) • The colony may be at risk by an infected individual • On economic grounds • Approved for a research project to terminate the life Methods of euthanasia • The methods can be divided into physical or chemical methods • Physical methods o Stunning
    [Show full text]
  • Cytochrome P450 Drug Interaction Table
    SUBSTRATES 1A2 2B6 2C8 2C9 2C19 2D6 2E1 3A4,5,7 amitriptyline bupropion paclitaxel NSAIDs: Proton Pump Beta Blockers: Anesthetics: Macrolide antibiotics: caffeine cyclophosphamide torsemide diclofenac Inhibitors: carvedilol enflurane clarithromycin clomipramine efavirenz amodiaquine ibuprofen lansoprazole S-metoprolol halothane erythromycin (not clozapine ifosfamide cerivastatin lornoxicam omeprazole propafenone isoflurane 3A5) cyclobenzaprine methadone repaglinide meloxicam pantoprazole timolol methoxyflurane NOT azithromycin estradiol S-naproxen_Nor rabeprazole sevoflurane telithromycin fluvoxamine piroxicam Antidepressants: haloperidol suprofen Anti-epileptics: amitriptyline acetaminophen Anti-arrhythmics: imipramine N-DeMe diazepam Nor clomipramine NAPQI quinidine 3OH (not mexilletine Oral Hypoglycemic phenytoin(O) desipramine aniline2 3A5) naproxen Agents: S-mephenytoin imipramine benzene olanzapine tolbutamide phenobarbitone paroxetine chlorzoxazone Benzodiazepines: ondansetron glipizide ethanol alprazolam phenacetin_ amitriptyline Antipsychotics: N,N-dimethyl diazepam 3OH acetaminophen NAPQI Angiotensin II carisoprodol haloperidol formamide midazolam propranolol Blockers: citalopram perphenazine theophylline triazolam riluzole losartan chloramphenicol risperidone 9OH 8-OH ropivacaine irbesartan clomipramine thioridazine Immune Modulators: tacrine cyclophosphamide zuclopenthixol cyclosporine theophylline Sulfonylureas: hexobarbital tacrolimus (FK506) tizanidine glyburide imipramine N-DeME alprenolol verapamil glibenclamide indomethacin
    [Show full text]
  • Flockhart Table – Medication Metabolism
    Flockhart Table ™ “The effective, intelligent management of many problems related to drug interactions in clinical prescribing can be helped by an understanding of how drugs are metabolized. Specifically, if a prescriber is aware of the dominant cytochrome P450 isoform involved in a drug's metabolism, it is possible to anticipate, from the inhibitor and inducer lists for that enzyme, which drugs might cause significant interactions.” • Substrates: drugs that are metabolized as substrates by the enzyme • Inhibitors: drugs that prevent the enzyme from metabolizing the substrates • Activators: drugs that increase the enzyme's ability to metabolize the substrates Taken from: http://medicine.iupui.edu/CLINPHARM/ddis/pocket-card Furthermore, Pocket Cards can be ordered from: http://medicine.iupui.edu/CLINPHARM/ddis/pocket-card The Flockhart Table™ is © 2016 by The Trustees of Indiana University. All rights reserved. Retrieved December 27, 2016, from http://medicine.iupui.edu/clinpharm/ddis/main-table P450 Drug Interaction Table SUBSTRATES drugs that are metabolized as substrates by the enzyme 1A2 2B6 2C8 2C9 2C19 2D6 2E1 3A4,5,7 amitriptyline artemisinin amodiaquine NSAIDs: PPIs: tamoxifen: Anesthetics: Macrolide 2 1 caffeine2 bupropion1 diclofenac esomeprazole TAMOXIFEN enflurane antibiotics: clomipramine cyclophosphamid cerivastatin ibuprofen lansoprazole GUIDE halothane clarithromycin clozapine e paclitaxel lornoxicam omeprazole2 isoflurane erythromycin2 cyclobenzaprine efavirenz1 repaglinide meloxicam pantoprazole Beta Blockers: methoxyflurane
    [Show full text]
  • Chronic Cardiac Toxicity After Inhalation Of1,1,1-Trichloroethane
    BRITISH MEDICAL JOURNAL VOLUME 294 21 MARCH 1987 727 Br Med J (Clin Res Ed): first published as 10.1136/bmj.294.6574.727 on 21 March 1987. Downloaded from CLINICAL RESEARCH Chronic cardiac toxicity after inhalation of 1,1,1-trichloroethane ANDREW A McLEOD, ROBERT MARJOT, MARK J MONAGHAN, PHILIP HUGH-JONES, GRAHAM JACKSON Abstract 1,1,1-trichloroethane produced serious cardiac toxicity. Anaes- thesia with halothane was induced in both patients for non-related Two patients showed evidence of chronic cardiac toxicity after conditions and was followed by a deterioration in cardiac rhythm or repeated exposure to 1,1,1-trichloroethane. In both cases there performance. was circumstantial -evidence of a deterioration after routine anaesthetic use of the related compound halothane. An ado- lescent boy who sniffed trichloroethane presented with multiple ventricular arrhythmias during tonsillectomy. Follow up showed Case histories mild chronic left ventricular impairment. A 54 year old man had repeated industrial exposure to trichloroethane and deteriorated CASE 1 from mild stable cardiac failure to end stage cardiac failure after A 14 year old boy was well-before tonsillectomy but was noted to have halothane anaesthesia for herniorrhaphy. Chronic cardiac multiple ventricular extrasystoles after the start of anaesthesia. Pre- toxicity is a previously unreported feature of this type of solvent medication was with papaveretum 10 mg and hyoscine hydrobromide 0-2 mgintramuscularly. Induction was with thiopentone 200 mg followed by http://www.bmj.com/ exposure. gallamine 10 mg, and paralysis was achieved with suxamethonium7-5 mg. Related compounds such as halothane may have a toxic The patient was maintained with nitrous oxide, oxygen, and halothane.
    [Show full text]
  • AVMA Guidelines for the Euthanasia of Animals: 2020 Edition*
    AVMA Guidelines for the Euthanasia of Animals: 2020 Edition* Members of the Panel on Euthanasia Steven Leary, DVM, DACLAM (Chair); Fidelis Pharmaceuticals, High Ridge, Missouri Wendy Underwood, DVM (Vice Chair); Indianapolis, Indiana Raymond Anthony, PhD (Ethicist); University of Alaska Anchorage, Anchorage, Alaska Samuel Cartner, DVM, MPH, PhD, DACLAM (Lead, Laboratory Animals Working Group); University of Alabama at Birmingham, Birmingham, Alabama Temple Grandin, PhD (Lead, Physical Methods Working Group); Colorado State University, Fort Collins, Colorado Cheryl Greenacre, DVM, DABVP (Lead, Avian Working Group); University of Tennessee, Knoxville, Tennessee Sharon Gwaltney-Brant, DVM, PhD, DABVT, DABT (Lead, Noninhaled Agents Working Group); Veterinary Information Network, Mahomet, Illinois Mary Ann McCrackin, DVM, PhD, DACVS, DACLAM (Lead, Companion Animals Working Group); University of Georgia, Athens, Georgia Robert Meyer, DVM, DACVAA (Lead, Inhaled Agents Working Group); Mississippi State University, Mississippi State, Mississippi David Miller, DVM, PhD, DACZM, DACAW (Lead, Reptiles, Zoo and Wildlife Working Group); Loveland, Colorado Jan Shearer, DVM, MS, DACAW (Lead, Animals Farmed for Food and Fiber Working Group); Iowa State University, Ames, Iowa Tracy Turner, DVM, MS, DACVS, DACVSMR (Lead, Equine Working Group); Turner Equine Sports Medicine and Surgery, Stillwater, Minnesota Roy Yanong, VMD (Lead, Aquatics Working Group); University of Florida, Ruskin, Florida AVMA Staff Consultants Cia L. Johnson, DVM, MS, MSc; Director,
    [Show full text]
  • Nitrous Oxide Use in Children
    Rev Bras Anestesiol SPECIAL ARTICLE 2012; 62: 3: 451-467 SPECIAL ARTICLE Nitrous Oxide Use in Children Leonardo Teixeira Domingues Duarte 1, Gastão Fernandes Duval Neto 2, Florentino Fernandes Mendes 3 Summary: Duarte LTD, Duval Neto GF, Mendes FF – Nitrous Oxide Use in Children. ©2012 Elsevier Editora Ltda. All rights reserved. DESCRIPTION OF THE EVIDENCE COLLECTION 11. Nitrous Oxide [MeSH] AND Anesthesia, General METHOD [MeSH] AND Child [MeSH] AND Randomized Con- trolled Trial[ptyp] Searches were carried out in multiple databases (Medline 12. Pediatrics [MeSH] OR Neonatology [MeSH] AND Ni- 1965 to 2009, Cochrane Library, LILACS) and cross-referenc- trous Oxide [MeSH] es with the collected material to identify articles with better 13. Nitrous Oxide [MeSH] AND Anesthesia, General methodological design, followed by critical evaluation of their [MeSH] AND Pediatrics [MeSH] AND Randomized content and classification according with the strength of evi- Controlled Trial[ptyp] dence. 14. Nitrous Oxide [MeSH] AND Anesthesia, General Searches occurred between December 2007 and April [MeSH] AND Neonatology [MeSH] AND Randomized 2008. The following search strategies were used for searches Controlled Trial[ptyp] in PubMed: 15. Cerebral Palsy [MeSH] AND Child [MeSH] AND Ni- trous Oxide [MeSH] 1. Nitrous Oxide [MeSH] AND Pharmacology [MeSH] AND Toxicology [MeSH] Studies comparing different classes of anesthetic drugs or 2. Nitrous Oxide [MeSH] AND Toxicology [MeSH] sedation techniques in children undergoing diagnostic tests 3. Nitrous Oxide [MeSH] AND toxicity [subheading] or procedures with the use of sedation or anesthesia were 4. Nitrous Oxide [MeSH] AND Acute Toxicity Tests selected. Also selected were studies that evaluated the phar- [MeSH] OR Toxicity Tests [MeSH] macological effects of nitrous oxide, its interaction with other 5.
    [Show full text]
  • AVMA Guidelines for the Euthanasia of Animals: 2013 Edition
    AVMA Guidelines for the Euthanasia of Animals: 2013 Edition Members of the Panel on Euthanasia Steven Leary, DVM, DACLAM (Chair); Washington University, St. Louis, Missouri Wendy Underwood, DVM (Vice Chair); Eli Lilly and Company, Indianapolis, Indiana Raymond Anthony, PhD (Ethicist); University of Alaska Anchorage, Anchorage, Alaska Samuel Cartner, DVM, MPH, PhD, DACLAM (Lead, Laboratory Animals Working Group); University of Alabama at Birmingham, Birmingham, Alabama Douglas Corey, DVM (Lead, Equine Working Group); Associated Veterinary Clinic, Walla Walla, Washington Temple Grandin, PhD (Lead, Physical Methods Working Group); Colorado State University, Fort Collins, Colorado Cheryl Greenacre, DVM, DABVP (Lead, Avian Working Group); University of Tennessee, Knoxville, Tennessee Sharon Gwaltney-Brant, DVM, PhD, DABVT, DABT (Lead, Noninhaled Agents Working Group); ASPCA Poison Control Center, Urbana, Illinois Mary Ann McCrackin, DVM, PhD, DACVS (Lead, Companion Animals Working Group); Virginia Polytechnic Institute and State University, Blacksburg, Virginia Robert Meyer, DVM, DACVA (Lead, Inhaled Agents Working Group); Mississippi State University, Mississippi State, Mississippi David Miller, DVM, PhD, DACZM (Lead, Reptiles, Zoo and Wildlife Working Group); Loveland, Colorado Jan Shearer, DVM, MS, DACAW (Lead, Animals Farmed for Food and Fiber Working Group); Iowa State University, Ames, Iowa Roy Yanong, VMD (Lead, Aquatics Working Group); University of Florida, Ruskin, Florida AVMA Staff Consultants Gail C. Golab, PhD, DVM, MANZCVS, DACAW;
    [Show full text]
  • Medications in the Breast-Feeding Mother JEANNE P
    Medications in the Breast-Feeding Mother JEANNE P. SPENCER, M.D., Conemaugh Memorial Medical Center, Johnstown, Pennsylvania LUIS S. GONZALEZ III, PHARM.D., Conemaugh Memorial Medical Center, Johnstown, Pennsylvania DONNA J. BARNHART, PHARM.D, Johnstown, Pennsylvania Prescribing medications for a breast-feeding mother requires weighing the benefits of medication use for the mother against the risk of not breast-feeding the infant or the potential risk of exposing the infant to medications. A drug that is safe for use during pregnancy may not be safe for the nurs- ing infant. The transfer of medications into breast milk depends on a concentration gradient that allows passive diffusion of nonionized, non–protein-bound drugs. The infant’s medication exposure can be limited by prescribing medications to the breast-feeding mother that are poorly absorbed orally, by avoiding breast-feeding during times of peak maternal serum drug concentration and by prescribing topical therapy when possible. Mothers of premature or otherwise compromised infants may require altered dosing to avoid drug accumulation and toxicity in these infants. The most accu- rate and up-to-date sources of information, including Internet resources and telephone consulta- tions, should be used. (Am Fam Physician 2001;64:119-26.) hysicians receive little education largely determined by the maternal serum about breast-feeding and even drug concentration. This serum concentra- less training on the effects of tion tends to be lower with medications that maternal medications on the have large volumes of distribution and fluctu- nursing infant.1 Yet, concern ates more with medications that have short Pabout potential harm to the nursing infant half-lives.
    [Show full text]